Treatment of Zollinger-Ellison syndrome

World Journal of Gastroenterology

Volumn 11, Issue 35, 2005, Pages 5423-5432

  Tomassetti, Paola ^a   Campana, Davide ^a   Piscitelli, Lydia ^a   Mazzotta, Elena ^a   Brocchi, Emilio ^a   Pezzilli, Raffaele ^a   Corinaldesi, Roberto ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Chemoembolization; Gastrinoma; MEN 1; Proton pump inhibitors; Somatostatin analogs; Zollinger Ellison syndrome

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; ANTINEOPLASTIC AGENT; CHLOROZOTOCIN; CYANOCOBALAMIN; DACARBAZINE; DOXORUBICIN; ESOMEPRAZOLE; FLUOROURACIL; GASTRIN; GELFOAM; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; LONG ACTING DRUG; OCTREOTIDE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; SOMATOSTATIN DERIVATIVE; STOMACH SECRETION INHIBITOR; STREPTOZOCIN;

ABDOMINAL PAIN; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CHEMOEMBOLIZATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG RELEASE; ECHOGRAPHY; ENDOCRINE TUMOR; GALLSTONE; GASTRINOMA; GASTROINTESTINAL TOXICITY; HELICOBACTER INFECTION; HORMONE RELEASE; HUMAN; INJECTION PAIN; LIVER METASTASIS; LONG TERM CARE; MEDLINE; MULTIPLE ENDOCRINE NEOPLASIA; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PHARMACODYNAMICS; REVIEW; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TACHYPHYLAXIS; TUMOR GROWTH; ZOLLINGER ELLISON SYNDROME;

EID: 28044469284     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i35.5423     Document Type: Review

References (115)

1. Zollinger RM, Ellison EH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. 1955. CA Cancer J Clin 1989; 39: 231-247
2. Jensen RT, Gardner JD, Raufman JP, Pandol SJ, Doppman JL, Collen MJ. Zollinger-Ellison syndrome: current concepts and management. Ann Intern Med 1983; 98: 59-75
3. Jensen RT, Doppman JL, Gardner JD. Gastrinoma. In: Go V. LW, Brooks FA, DiMagno EP, Gardner JD, Lebenthal E, Scheele GA, eds. The exlocrine pancreas: biology, pathobiology and disease. New York: Raven Press 1986: 727-744
4. Norton JA, Jensen RT. Current surgical management of Zollinger-Ellison syndrome (ZES) in patients without multiple endocrine neoplasia-type 1 (MEN1). Surg Oncol 2003; 12: 145-151
5. Pipeleers-Marichal M, Somers G, Willems G, Foulis A, Imrie C, Bishop AE, Polak JM, Hacki WH, Stamm B, Heitz PU. Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome. N Engl J Med 1990; 322: 723-727
6. Jensen RT. Zollinger-Ellison syndrome. In: Doherty GM, Skogseid B, eds. Surgical endocrinology: clinical syndromes. Philadelphia 2001: 291-344
7. Soga J, Yakuwa Y. The gastrinoma/Zollinger-Ellison syndrome: statistical evaluation of a Japanese series of 359 cases. J Hepatobiliary Pancreat Surg 1998; 5: 77-85
8. Gibril F, Curtis LT, Termanini B, Fritsch MK, Lubensky IA, Doppman JL, Jensen RT. Primary cardiac gastrinoma causing Zollinger-Ellison syndrome. Gastroenterology 1997; 112: 567-574
9. Noda S, Norton JA, Jensen RT, Gay WA Jr. Surgical resection of intracardiac gastrinoma. Ann Thorac Surg 1999; 67: 532-533
10. Bou-Saif A, Lei J, McDonald TJ, Chakrabarti S, Waxman IF, Shojamanesh H, Schrump DS, Kleiner DE, Gibril F, Jensen RT. A new cause of Zollinger-Ellison syndrome: non-small cell lung cancer. Gastroenterology 2001; 120: 1271-1278
11. Zollinger RM, Ayres HP. The Zollinger-Ellison syndrome. In: Nyhus LM, Wastell C, Donahue PhE, eds. Surgery of the Esophagus, Stomach and Small Intestine 1987: 491-513
12. Isenberg JI, Walsh JH, Grossman MI. Zollinger-Ellison syndrome. Gastroenterology 1973; 65: 140-165
13. Ellison EC, Wilson SD. The Zollinger-Ellison syndrome: reappraisal and evaluation of 260 registered cases. Ann Surg 1964; 160: 512-530
14. Stage JG, Stadil F. The clinical diagnosis of the Zollinger-Ellison syndrome. Scand J Gastroenterol Suppl 1979; 53: 79-91
15. Yu F, Venzon DJ, Serrano J, Goebel SU, Doppman JL, Gibril F, Jensen RT. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol 1999; 17: 615-630
16. Weber HC, Venzon DJ, Lin JT, Fishbein VA, Orbuch M, Strader DB, Gibril F, Metz DC, Fraker DL, Norton JA. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 1995; 108: 1637-1649
17. Durieux S, Liote F, Timsit MA, Duet M, Valleur P, Lemaire V, Dryll A. Bone metastases in epidural invasion of gastrinoma. Rev Rhum Ed Fr 1994; 61: 453-455
18. Maton PN. Gastrinoma and other hypergastrinemic syndrome. In: Walsh JH, Dockray GJ, eds. Gut Peptides. New York: Raven Press 1994: 675-700
19. Ruszniewski P, Girard F, Benamouzig R, Mignon M, Bonfils S. Long acting somatostatin treatment of paraneoplastic Cushing's syndrome in a case of Zollinger-Ellison syndrome. Gut 1988; 29: 838-842
20. Wermer P. Genetic aspects of adenomatosis of endocrine glands. Am J Med 1954; 16: 363-371
21. Shepherd JJ. The natural history of multiple endocrine neoplasia type 1. Highly uncommon or highly unrecognized? Arch Surg 1991; 126: 935-952
22. Larsson C, Skogseid B, Oberg K, Nakamura Y, Nordenskjold M. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988; 332: 85-87
23. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, Crabtree JS, Wang Y, Roe BA, Weisemann J, Boguski MS, Agarwal SK, Kester MB, Kim YS, Heppner C, Dong Q, Spiegel AM, Burns AL, Marx SJ. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997; 276: 404-407
24. Heppner C, Kester MB, Agarwal SK, Debelenko LV, Emmert-Buck MR, Guru SC, Manickam P, Olufemi SE, Skarulis MC, Doppman JL, Alexander RH, Kim YS, Saggar SK, Lubensky IA, Zhuang Z, Liotta LA, Chandrasekharappa SC, Collins FS, Spiegel AM, Burns AL, Marx SJ. Somatic mutation of the MEN1 gene in parathyroid tumours. Nat Genet 1997; 16: 375-378
25. Zhuang Z, Vortmeyer AO, Pack S, Huang S, Pham TA, Wang C, Park WS, Agarwal SK, Debelenko LV, Kester M, Guru SC, Manickam P, Olufemi SE, Yu F, Heppner C, Crabtree JS, Skarulis MC, Venzon DJ, Emmert-Buck MR, Spiegel AM, Chandrasekharappa SC, Collins FS, Burns AL, Marx SJ, Lubensky IA. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res 1997; 57: 4682-4686
26. Debelenko LV, Brambilla E, Agarwal SK, Swalwell JI, Kester MB, Lubensky IA, Zhuang Z, Guru SC, Manickam P, Olufemi SE, Chandrasekharappa SC, Crabtree JS, Kim YS, Heppner C, Burns AL, Spiegel AM, Marx SJ, Liotta LA, Collins FS, Travis WD, Emmert-Buck MR. Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. Hum Mol Genet 1997; 6: 2285-2290
27. Rindi G, Villanacci V, Ubiali A. Biological and molecular aspects of gas troenteropancreatic neuroendocrine tumors. Digestion 2000; 62 (Suppl 1): 19-26
28. Calender A. Molecular genetics of neuroendocrine tumors. Digestion 2000; 62 (Suppl 1): 3-18
29. Norton JA, Jensen RT. Multiple endocrine neoplasia. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer Principies and practice of oncology. Philadelphia: Lippincott Raven Publisher 1997: 1723-1729
30. Gibril F, Schumann M, Pace A, Jensen RT. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine 2004; 83: 43-83
31. Benya RV, Metz DC, Venzon DJ, Fishbeyn VA, Strader DB, Orbuch M, Jensen RT. Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type I. Am J Med 1994; 97: 436-444
32. Mignon M, Cadiot G, Rigaud D, Ruszniewski PH, Jais P, Lehy T, Lewin MJM. Management of islet cell tumors in patients with multiple endocrine neoplasia type 1. In: Mignon M, Jensen RT eds. Endocrine tumors of the pancreas: Recent advances in research and management. Karger[231 1995: 342-359
33. Tomassetti P, Migliori M, Lalli S, Campana D, Tomassetti V, Corinaldesi R. Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours. Ann Oncol 2001; 12 (Suppl 2): S95-99
34. Jensen RT. Gastrointestinal endocrine tumours. Gastrinoma. Baillieres Clin Gastroenterol 1996; 10: 603-643
35. Lehy T, Cadiot G, Mignon M, Ruszniewski P, Bonfils S. Influence of multiple endocrine neoplasia type 1 on gastric endocrine cells in patients with the Zollinger-Ellison syndrome. Gut 1992; 33: 1275-1279
36. Jensen RT. Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med 1998; 243: 477-488
37. Rindi G, Bordi C, Rappel S, La Rosa S, Stolte M, Solcia E. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg 1996; 20: 168-172
38. Solcia E, Rindi G, Larosa S, Capella C. Morphological, molecular, and prognostic aspects of gastric endocrine tumors. Microsc Res Tech 2000; 48: 339-348
39. Roy PK, Venzon DJ, Shojamanesh H, Abou-Saif A, Peghini P, Doppman JL, Gibril F, Jensen RT. Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine 2000; 79: 379-411
40. Roy PK, Venzon DJ, Feigenbaum KM, Koviack PD, Bashir S, Ojeaburu JV, Gibril F, Jensen RT. Gastric secretion in Zollinger-Ellison syndrome. Correlation with clinical expression, tumor extent and role in diagnosis-a prospective NIH study of 235 patients and a review of 984 cases in the literature. Medicine 2001; 80: 189-222
41. Frucht H, Howard JM, Slaff JI, Wank SA, McCarthy DM, Maton PN, Vinayek R, Gardner JD, Jensen RT. Secretin and calcium provocative tests in the Zollinger-Ellison syndrome. A prospective study. Ann Intern Med 1989; 111: 713-722
42. Tartaglia A, Bianchini S, Vezzadini P. Biochemical diagnosis of gastroenteropancreatic endocrine tumors. Minerva Med 2003; 94: 1-7
43. Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ, Termanini B, Weber HC, Stewart CA, Jensen RT. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 1996; 125: 26-34
44. van Eijck CH, Lamberts SW, Lemaire LC, Jeekel H, Bosman FT, Reubi JC, Bruining HA, Krenning EP. The use of somatostatin receptor scintigraphy in the differential diagnosis of pancreatic duct cancers and islet cell tumors. Ann Surg 1996; 224: 119-124
45. London JF, Shawker TH, Doppman JL, Frucht HH, Vinayek R, Stark HA, Miller LS, Miller DL, Norton JA, Jensen RT. Zollinger-Ellison syndrome: prospective assessment of abdominal US in the localization of gastrinomas. Radiology 1991; 178: 763-767
46. Rosch T, Lightdale CJ, Botet JF, Boyce GA, Sivak MV Jr, Yasuda K, Heyder N, Palazzo L, Dancygier H, Schusdziarra V. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med 1992; 326: 1721-1726
47. Glover JR, Shorvon PJ, Lees WR. Endoscopic ultrasound for localisation of islet cell tumours. Gut 1992; 33: 108-110
48. Anderson MA, Carpenter S, Thompson NW, Nostrant TT, Elta GH, Scheiman JM. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol 2000; 95: 2271-2277
49. Ruszniewski P, Amouyal P, Amouyal G, Grange JD, Mignon M, Bouche O, Bernades P. Localization of gastrinomas by endoscopic ultrasonography in patients with Zollinger-Ellison syndrome. Surgery 1995; 117: 629-635
50. Van HL, Gryspeerdt S, Marchal G, Baert AL, Mertens L. Helical CT for the preoperative localization of islet cell tumors of the pancreas: value of arterial and parenchymal phase images. Am J Roentgenol 1995; 165: 1437-1439
51. Legmann P, Vignaux O, Dousset B, Baraza AJ, Palazzo L, Dumontier I, Coste J, Louvel A, Roseau G, Couturier D, Bonnin A. Pancreatic tumors: comparison of dual-phase helical CT and endoscopic sonography. Am J Roentgenol 1998; 170: 1315-1322
52. Semelka RC, Cumming MJ, Shoenut JP, Magro CM, Yaffe CS, Kroeker MA, Greenberg HM. Islet cell tumors: comparison of dynamic contrast-enhanced CT and MR imaging with dynamic gadolinium enhancement and fat suppression. Radiology 1993; 186: 799-802
53. Debray MP, Geoffroy O, Laissy JP, Lebtahi R, Silbermann-Hoffman O, Henry-Feugeas MC, Cadiot G, Mignon M, Schouman-Claeys E. Imaging appearances of metastases from neuroendocrine tumours of the pancreas. Br J Radiol 2001; 74: 1065-1070
54. Wiedenmann B, Jensen RT, Mignon M, Modlin CI, Skogseid B, Doherty G, Oberg K. Preoperative diagnosis and surgical management of neuroendocrine gastroenteropancreatic tumors: general recommendations by a consensus workshop. World J Surg 1998; 22: 309-318
55. Ricke J, Klose KJ, Mignon M, Oberg K, Wiedenmann B. Standardisation of imaging in neuroendocrine tumours: results of a European delphi process. Eur J Radiol 2001; 37: 8-17
56. Maton PN, Miller DL, Doppman JL, Collen MJ, Norton JA, Vinayek R, Slaff JI, Wank SA, Gardner JD, Jensen RT. Role of selective angiography in the management of patients with Zollinger-Ellison syndrome. Gastroenterology 1987; 92: 913-918
57. Roche A, Raisonnier A, Gillon-Savouret MC. Pancreatic venous sampling and arteriography in localizing insulinomas and gastrinomas: procedure and results in 55 cases. Radiology 1982; 145: 621-627
58. Norton JA, Fraker DL, Alexander HR, Venzon DJ, Doppman JL, Serrano J, Goebel SU, Peghini PL, Roy PK, Gibril F, Jensen RT. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 1999; 341: 635-644
59. Lew EA, Pisegna JR, Starr JA, Soffer EF, Forsmark C, Modlin IM, Walsh JH, Beg M, Bochenek W, Metz DC. Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology 2000; 118: 696-704
60. Howard JM, Chremos AN, Collen MJ, McArthur KE, Cherner JA, Maton PN, Ciarleglio CA, Cornelius MJ, Gardner JD, Jensen RT. Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome. Gastroenterology 1985; 88: 1026-1033
61. Jensen RT, Collen MJ, McArthur KE, Howard JM, Maton PN, Cherner JA, Gardner JD. Comparison of the effectiveness of ranitidine and cimetidine in inhibiting acid secretion in patients with gastric hypersecretory states. Am J Med 1984; 77: 90-105
62. Jensen RT, Maton PN, Gardner JD. Current management of Zollinger-Ellison syndrome. Drugs 1986; 32: 188-196
63. Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc 2000; 40: 52-62
64. Thomson AB. Are the orally administered proton pump inhibitors equivalent? a comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole. Curr Gastroenterol Rep 2000; 2: 482-493
65. Metz DC, Strader DB, Orbuch M, Koviack PD, Feigenbaum KM, Jensen RT. Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety. Aliment Pharmacol Ther 1993; 7: 597-610
66. Jensen RT, Gardner JD. Zollinger-Ellison syndrome: clinical presentation, pathology, diagnosis and treatment. In: Zakim D, Dannenberg AJ, eds. Peptic ulcer disease and other acid-related disorder. New York Accademic Research Associates 1991: 117-246
67. Metz MD, Jensen RT. Advances in gastric antisecretory therapy in Zollinger-Ellison syndrome. Mignon M, Jensen RT, eds. Endocrine tumors of the pancreas: Recent advances in research and management. Karger[23] 1995: 240-257
68. Termanini B, Gibril F, Stewart CA, Weber HC, Jensen RT. A prospective study of the effectiveness of low dose omeprazole as initial therapy in Zollinger-Ellison syndrome. Aliment Pharmacol Ther 1996; 10: 61-71
69. Stadil F, Stage JG. The Zollinger-Ellison syndrome. Clin Endocrinol Metab 1979; 8: 433-446
70. Metz DC, Pisegna JR, Fishbeyn VA, Benya RV, Feigenbaum KM, Koviack PD, Jensen RT. Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology 1992; 103: 1498-1508
71. Andersson T, Bergstrand R, Cederberg C, Eriksson S, Lagerstrom PO, Skanberg I. Omeprazole treatment does not affect the metabolism of caffeine. Gastroenterology 1991; 101: 943-947
72. Jansen JB, Lundborg P, Baak LC, Greve J, Ohman M, Stover C, Rohss K, Lamers CB. Effect of single and repeated intravenous doses of omeprazole on pentagastrin stimulated gastric acid secretion and pharmacokinetics in man. Gut 1988; 29: 75-80
73. Lloyd-Davies KA, Rutgersson K, Solvell L. Omeprazole in the treatment of Zollinger-Ellison syndrome: a 4-year international study. Aliment Pharmacol Ther 1988; 2: 13-32
74. Wolfe MM, Jensen RT. Zollinger-Ellison syndrome. Current concepts in diagnosis and management. N Engl J Med 1987; 317: 1200-1209
75. Maton PN, Lack EE, Collen MJ, Cornelius MJ, David E, Gardner JD, Jensen RT. The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells. Gastroenterology 1990; 99: 943-950
76. Howden CW. Vitamin B12 levels during prolonged treatment with proton pump inhibitors. J Clin Gastroenterol 2000; 30: 29-33
77. Weber HC, Venzon DJ, Jensen RT, Metz DC. Studies on the interrelation between Zollinger-Ellison syndrome, Helicobacter pylori, and proton pump inhibitor therapy. Gastroenterology 1997; 112: 84-91
78. Ruszniewski P, Laucournet H, Elouaer-Blanc L, Mignon M, Bonfils S. Long-acting somatostatin (SMS 201-995) in the management of Zollinger-Ellison syndrome: evidence for sustained efficacy. Pancreas 1988; 3: 145-152
79. Tomassetti P, Migliori M, Gullo L. Slow-release lanreotide treatment in endocrine gastrointestinal tumors. Am J Gastroenterol 1998; 93: 1468-1471
80. Tomassetti P, Migliori M, Corinaldesi R, Gullo L. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment Pharmacol Ther 2000; 14: 557-560
81. Arnold R, Simon B, Wied M. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review. Digestion 2000; 62 (Suppl 1): 84-91
82. Bordi C, Azzoni C, Pilato FP, Robutti F, D'Ambra G, Caruana P, Rindi G, Corleto VD, Annibale B, Delle FG. Morphometry of gastric endocrine cells in hypergastrinemic patients treated with the somatostatin analogue octreotide. Regul Pept 1993; 47: 307-318
83. Arnold R, Trautmann ME, Creutzfeldt W, Benning R, Benning M, Neuhaus C, Jurgensen R, Stein K, Schafer H, Bruns C, Dennler HJ. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996; 38: 430-438
84. Jensen RT. Carcinoid and pancreatic endocrine tumors: recent advances in molecular pathogenesis, localization, and treatment. Curr Opin Oncol 2000; 12: 368-377
85. Shojamanesh H, Gibril F, Louie A, Ojeaburu JV, Bashir S, Abou-Saif A, Jensen RT. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer 2002; 94: 331-343
86. Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C, Bartolomei M, Orsi F, De Cicco C, Macke HR, Chinol M, de Braud F. Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. Eur J Nucl Med 2001; 28: 426-434
87. Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001; 12: 941-945
88. Leimer M, Kurtaran A, Smith-Jones P, Raderer M, Havlik E, Angelberger P, Vorbeck F, Niederle B, Herold C, Virgolini I. Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma. J Nucl Med 1998; 39: 2090-2094
89. Peghini PL, Annibale B, Azzoni C, Milione M, Corleto VD, Gibril F, Venzon DJ, Delle FG, Bordi C, Jensen RT. Effect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas. Gastroenterology 2002; 123: 68-85
90. Cadiot G, Lehy T, Bonfils S. Action of somatostatin analogue (SMS 201-995) on the growth-promoting effect resulting from sustained achlorhydria in rat gastric mucosa, with special reference to endocrine cell behaviour. Eur J Clin Invest 1988; 18: 360-368
91. Modlin IM, Kumar R, Nangia A, Soroka CJ, Pasikhov D, Goldenring JR. Gastrin-dependent inhibitory effects of octreotide on the genesis of gastric ECLomas. Surgery 1992; 112: 1048-1056
92. Tomassetti P, Migliori M, Caletti GC, Fusaroli P, Corinaldesi R, Gullo L. Treatment of type II gastric carcinoid tumors with somatostatin analogues. N Engl J Med 2000; 343: 551-554
93. Fraker DL, Norton JA, Alexander HR, Venzon DJ, Jensen RT. Surgery in Zollinger-Ellison syndrome alters the natural history of gastrinoma. Ann Surg 1994; 220: 320-328
94. Hirschowitz BI. Clinical course of nonsurgically treated Zollinger-Ellison syndrome. Mignon M, Jensen RT, eds. Endocrine tumors of the pancreas: Recent advances in research and management. Karger[23] 1995: 360-371
95. Thompson NW, Bondeson AG, Bondeson L, Vinik A. The surgical treatment of gastrinoma in MEN I syndrome patients. Surgery 1989; 106: 1081-1085
96. Delcore R, Cheung LY, Friesen SR. Outcome of lymph node involvement in patients with the Zollinger-Ellison syndrome. Ann Surg 1988; 208: 291-298
97. Fraker DL, Norton JA, Saeed ZA, Maton PN, Gardner JD, Jensen RT. A prospective study of perioperative and postoperative control of acid hypersecretion in patients with Zollinger-Ellison syndrome undergoing gastrinoma resection. Surgery 1988; 104: 1054-1063
98. Azoulay D, Bismuth H. Role of liver surgery and transplantation in patients with hepatic metastases from pancreatic endocrine tumors. Mignon M, Jensen RT, eds. Endocrine tumors of the pancreas: Recent advances in research and management. Karger[23] 1995: 461-476
99. Le Treut YP, Delpero JR, Dousset B, Cherqui D, Segol P, Mantion G, Hannoun L, Benhamou G, Launois B, Boillot O, Domergue J, Bismuth H. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report. Ann Surg 1997; 225: 355-364
100. Thompson NW. Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease. Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both. J Intern Med 1998; 243: 495-500
101. Akerstrom G, Hessman O, Skogseid B. Timing and extent of surgery in symptomatic and asymptomatic neuroendocrine tumors of the pancreas in MEN 1. Langenbecks Arch Surg 2002; 386: 558-569
102. Thompson NW, Pasieka J, Fukuuchi A. Duodenal gastrinomas, duodenotomy, and duodenal exploration in the surgical management of Zollinger-Ellison syndrome. World J Surg 1993; 17: 455-462
103. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SA Jr, Marx SJ. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86: 5658-5671
104. Arnold R, Frank M. Systemic chemotherapy for endocrine tunors of the pancreas. Mignon M, Jensen RT, eds. Endocrine tumors of the pancreas: Recent advances in research and management. Karger[23] 1995: 431-438
105. Murray-Lyon IM, Eddleston AL, Williams R, Brown M, Hogbin BM, Bennett A, Edwards JC, Taylor KW. Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin. Lancet 1968; 2: 895-898
106. Broder LE, Carter SK. Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med 1973; 79: 108-118
107. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992; 326: 519-523
108. von Schrenck T, Howard JM, Doppman JL, Norton JA, Maton PN, Smith FP, Vinayek R, Frucht H, Wank SA, Gardner JD. Prospective study of chemotherapy in patients with metastatic gastrinoma. Gastroenterology 1988; 94: 1326-1334
109. Kvols LK, Buck M. Chemotherapy of endocrine malignancies: a review. Semin Oncol 1987; 14: 343-353
110. Rougier P, Mitry E. Chemotherapy in the treatment of neuroendocrine malignant tumors. Digestion 2000; 62 (Suppl 1): 73-78
111. Oberg K. Advances in chemotherapy and biotherapy of endocrine tumors. Curr Opin Oncol 1998; 10: 58-65
112. Clouse ME, Perry L, Stuart K, Stokes KR. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Digestion 1994; 55(Suppl 3): 92-97
113. Perry LJ, Stuart K, Stokes KR, Clouse ME. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery 1994; 116: 1111-1116
114. Drougas JG, Anthony LB, Blair TK, Lopez RR, Wright JK Jr, Chapman WC, Webb L, Mazer M, Meranze S, Pinson CW. Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors. Am J Surg 1998; 175: 408-412
115. Kress O, Wagner HJ, Wied M, Klose KJ, Arnold R, Alfke H. Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors-a retrospective single-center analysis. Digestion 2003; 68: 94-101